Pharmaceuticals 2010, 3(7), 2197-2212; doi:10.3390/ph3072197

Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke

* email, email and email
Received: 10 June 2010; in revised form: 29 June 2010 / Accepted: 6 July 2010 / Published: 8 July 2010
(This article belongs to the Special Issue Cannabinoids)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Cannabis contains the psychoactive component delta9-tetrahydrocannabinol (delta9-THC), and the non-psychoactive components cannabidiol (CBD), cannabinol, and cannabigerol. It is well-known that delta9-THC and other cannabinoid CB1 receptor agonists are neuroprotective during global and focal ischemic injury. Additionally, delta9-THC also mediates psychological effects through the activation of the CB1 receptor in the central nervous system. In addition to the CB1 receptor agonists, cannabis also contains therapeutically active components which are CB1 receptor independent. Of the CB1 receptor-independent cannabis, the most important is CBD. In the past five years, an increasing number of publications have focused on the discovery of the anti-inflammatory, anti-oxidant, and neuroprotective effects of CBD. In particular, CBD exerts positive pharmacological effects in ischemic stroke and other chronic diseases, including Parkinson’s disease, Alzheimer’s disease, and rheumatoid arthritis. The cerebroprotective action of CBD is CB1 receptor-independent, long-lasting, and has potent anti-oxidant activity. Importantly, CBD use does not lead to tolerance. In this review, we will discuss the therapeutic possibility of CBD as a cerebroprotective agent, highlighting recent pharmacological advances, novel mechanisms, and therapeutic time window of CBD in ischemic stroke.
Keywords: cannabinoids; cannabidiol; ischemic stroke; neuroprotective effect
PDF Full-text Download PDF Full-Text [338 KB, uploaded 8 July 2010 13:50 CEST]

Export to BibTeX |

MDPI and ACS Style

Hayakawa, K.; Mishima, K.; Fujiwara, M. Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke. Pharmaceuticals 2010, 3, 2197-2212.

AMA Style

Hayakawa K, Mishima K, Fujiwara M. Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke. Pharmaceuticals. 2010; 3(7):2197-2212.

Chicago/Turabian Style

Hayakawa, Kazuhide; Mishima, Kenichi; Fujiwara, Michihiro. 2010. "Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke." Pharmaceuticals 3, no. 7: 2197-2212.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert